Last reviewed · How we verify

Active bupropion + counseling

University of Wisconsin, Madison · FDA-approved active Small molecule

Bupropion inhibits the reuptake of dopamine and norepinephrine in the central nervous system, increasing their availability to enhance mood and motivation, while counseling provides behavioral support for smoking cessation or other psychiatric conditions.

Bupropion inhibits the reuptake of dopamine and norepinephrine in the central nervous system, increasing their availability to enhance mood and motivation, while counseling provides behavioral support for smoking cessation or other psychiatric conditions. Used for Smoking cessation (with behavioral counseling), Major depressive disorder, Seasonal affective disorder.

At a glance

Generic nameActive bupropion + counseling
SponsorUniversity of Wisconsin, Madison
Drug classAntidepressant (dopamine-norepinephrine reuptake inhibitor)
TargetDopamine transporter (DAT), Norepinephrine transporter (NET)
ModalitySmall molecule
Therapeutic areaPsychiatry / Addiction Medicine
PhaseFDA-approved

Mechanism of action

Bupropion is an atypical antidepressant that works primarily as a dopamine and norepinephrine reuptake inhibitor (DNRI), distinct from serotonin-focused mechanisms. When combined with counseling, the pharmacological effects are augmented by behavioral intervention, addressing both neurochemical and psychological aspects of the condition. This combination approach is particularly effective for smoking cessation and depression management.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: